These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 7985276)
1. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis]. Nielsen JD; Landorph A Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276 [TBL] [Abstract][Full Text] [Related]
2. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Harenberg J; Huisman MV; Tolle AR; Breddin HK; Kirchmaier CM Semin Thromb Hemost; 2001 Oct; 27(5):513-8. PubMed ID: 11668421 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080 [TBL] [Abstract][Full Text] [Related]
4. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482 [TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Pini M; Tagliaferri A; Manotti C; Lasagni F; Rinaldi E; Dettori AG Int Angiol; 1989; 8(3):134-9. PubMed ID: 2556484 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Wein L; Wein S; Haas SJ; Shaw J; Krum H Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601 [TBL] [Abstract][Full Text] [Related]
8. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163 [TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Holzheimer RG Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403 [TBL] [Abstract][Full Text] [Related]
10. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Kakkar VV; Howes J; Sharma V; Kadziola Z Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310 [TBL] [Abstract][Full Text] [Related]
11. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651 [TBL] [Abstract][Full Text] [Related]
12. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312 [TBL] [Abstract][Full Text] [Related]
13. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke? Kamphuisen PW; Agnelli G Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999 [TBL] [Abstract][Full Text] [Related]
14. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis]. Marbet GA Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718 [TBL] [Abstract][Full Text] [Related]
16. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381 [TBL] [Abstract][Full Text] [Related]
17. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. Tapson VF; Hull RD Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521 [TBL] [Abstract][Full Text] [Related]
19. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Mismetti P; Laporte-Simitsidis S; Tardy B; Cucherat M; Buchmüller A; Juillard-Delsart D; Decousus H Thromb Haemost; 2000 Jan; 83(1):14-9. PubMed ID: 10669147 [TBL] [Abstract][Full Text] [Related]
20. [Therapeutic indications of low molecular weight heparins]. Samama MM; Michaut-Paterno F Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]